These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 23039898)

  • 1. Expenditures for medicaid patients treated with exenatide compared with other diabetes management regimens.
    Best JH; Romley JA; Goldman DP; Conrad RM; Peters AL
    Am J Manag Care; 2012 Sep; 18(8 Suppl):s191-202. PubMed ID: 23039898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
    Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
    J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine.
    Misurski D; Lage MJ; Fabunmi R; Boye KS
    Appl Health Econ Health Policy; 2009; 7(4):245-54. PubMed ID: 19905038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study.
    Holden SE; Morgan CL; Qiao Q; Jenkins-Jones S; Berni ER; Currie CJ
    Diabetes Obes Metab; 2017 Aug; 19(8):1097-1105. PubMed ID: 28218819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
    Bergeson JG; Worley K; Louder A; Ward M; Graham J
    J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy.
    Lage MJ; Fabunmi R; Boye KS; Misurski DA
    Adv Ther; 2009 Feb; 26(2):217-29. PubMed ID: 19219409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis.
    Pawaskar M; Zagar A; Sugihara T; Shi L
    J Med Econ; 2011; 14(1):16-27. PubMed ID: 21158486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
    Johnston SS; Nguyen H; Cappell K; Nelson JK; Chu BC; Kalsekar I
    J Med Econ; 2015; 18(9):666-77. PubMed ID: 25867133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of exenatide, pen insulin, and vial insulin on patient outcomes: a retrospective database analysis of persistence and first-year costs in a commercially insured population.
    Rashid N; McCombs JS; Schwartz E
    Clin Ther; 2012 May; 34(5):1145-58. PubMed ID: 22464691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide BID.
    Baser O; Wei W; Baser E; Xie L
    J Med Econ; 2011; 14(6):673-80. PubMed ID: 21892858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
    Gu S; Wang X; Qiao Q; Gao W; Wang J; Dong H
    Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
    Chuang LH; Verheggen BG; Charokopou M; Gibson D; Grandy S; Kartman B
    J Med Econ; 2016 Dec; 19(12):1127-1134. PubMed ID: 27310712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea).
    Cvetković RS; Plosker GL
    Drugs; 2007; 67(6):935-54. PubMed ID: 17428109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain.
    Fonseca T; Clegg J; Caputo G; Norrbacka K; Dilla T; Alvarez M
    J Med Econ; 2013 Jul; 16(7):926-38. PubMed ID: 23659201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus.
    Minshall ME; Oglesby AK; Wintle ME; Valentine WJ; Roze S; Palmer AJ
    Value Health; 2008; 11(1):22-33. PubMed ID: 18237357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
    Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
    Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
    Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
    Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus].
    Goodall G; Costi M; Timlin L; Reviriego J; Sacristán JA; Smith-Palmer J; Dilla T
    Endocrinol Nutr; 2011; 58(7):331-40. PubMed ID: 21719364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
    Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
    Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database.
    Best JH; Hoogwerf BJ; Herman WH; Pelletier EM; Smith DB; Wenten M; Hussein MA
    Diabetes Care; 2011 Jan; 34(1):90-5. PubMed ID: 20929995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.